Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. BLDR

Go back to Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Regeneron (NASDAQ: REGN) Delayed: 827.72 -15.75 (1.87%)
Previous Close $843.47    52 Week High $592.36 
Open $840.05    52 Week Low $325.35 
Day High $841.54    P/E 217.25 
Day Low $825.83    EPS $3.81 
Volume 561,170